Literature DB >> 3446162

Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.

D M Roberton1, C S Hosking, H Efthimiou, S Wright, H Upton, T Colgan, L Hartman, P Schiff.   

Abstract

Eighteen patients (ages eight months to 20 years) with disorders of immunoglobulin and antibody production received infusions of two preparations of intravenous immunoglobulin in a blind crossover trial. The incidence and severity of immediate adverse infusion reactions was significantly lower with low pH immunoglobulin; ten patients (56%) experiencing immediate reactions with the standard preparation and only one patient experiencing an immediate reaction with the low pH preparation (p less than 0.01). Infusion times were significantly less with the low pH preparation (p less than 0.02) and patient tolerance, determined by visual analogue scores, was significantly better than with the standard preparation (p less than 0.01). However, the incidence of delayed reactions (44%) was the same for both infusions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3446162     DOI: 10.1111/j.1445-5994.1987.tb00106.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Aseptic meningitis associated with high dose intravenous immunoglobulin therapy.

Authors:  J D Watson; J Gibson; D E Joshua; H Kronenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.

Authors:  N D Garbett; D C Currie; P J Cole
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93.

Authors:  S Skull; A Kemp
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 4.  Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.

Authors:  S A Schwartz
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.